Literature DB >> 1993898

Cholecystokinin modulates the release of dopamine from the anterior and posterior nucleus accumbens by two different mechanisms.

F H Marshall1, S Barnes, J Hughes, G N Woodruff, J C Hunter.   

Abstract

The effects of various cholecystokinin (CCK)-related peptides were investigated on 35 mM K(+)-stimulated endogenous dopamine release from slices of either anterior or posterior nucleus accumbens of the rat. CCK sulphated octapeptide (1-10 microM), but not pentagastrin or CCK unsulphated octapeptide, was found to cause a dose-dependent increase in the release from the posterior nucleus accumbens. This effect was blocked by low doses of the CCKA receptor antagonist L364,718 (10 nM) but not the CCKB receptor antagonist L365,260. In the anterior nucleus accumbens CCK sulphated octapeptide (1 microM) and CCK unsulphated octapeptide (0.1-1 microM) inhibited the dopamine release, and this effect was blocked by L365,260 (10-100 nM) but not by L364,718. These results suggest that CCK has a different effect on dopamine release from the anterior and posterior nucleus accumbens and that these effects are mediated by two different types of CCK receptor.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1993898     DOI: 10.1111/j.1471-4159.1991.tb02009.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  15 in total

1.  Brief intermittent access to sucrose differentially modulates prepulse inhibition and acoustic startle response in obese CCK-1 receptor deficient rats.

Authors:  Bart C De Jonghe; Carmine Di Martino; Andras Hajnal; Mihai Covasa
Journal:  Brain Res       Date:  2005-08-02       Impact factor: 3.252

2.  A cholecystokinin B receptor antagonist and cocaine interaction, phase I study.

Authors:  Ahmed Elkashef; James Robert Brašić; Louis R Cantelina; Roberta Kahn; Nora Chiang; Weiguo Ye; Yun Zhou; Jurij Mojsiak; Kimberly R Warren; Andrew Crabb; John Hilton; Dean F Wong; Frank Vocci
Journal:  CNS Neurosci Ther       Date:  2018-06-20       Impact factor: 5.243

3.  Devazepide, a CCKA receptor antagonist, impairs the acquisition of conditioned reward and conditioned activity.

Authors:  S A Josselyn; V P Franco; F J Vaccarino
Journal:  Psychopharmacology (Berl)       Date:  1996-01       Impact factor: 4.530

Review 4.  A Motivational and Neuropeptidergic Hub: Anatomical and Functional Diversity within the Nucleus Accumbens Shell.

Authors:  Daniel C Castro; Michael R Bruchas
Journal:  Neuron       Date:  2019-05-08       Impact factor: 17.173

5.  Effect of CCK receptor antagonists on the antinociceptive, reinforcing and gut motility properties of morphine.

Authors:  L Singh; R J Oles; M J Field; P Atwal; G N Woodruff; J C Hunter
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

6.  Cholecystokinin activates CCKB receptors to excite cells and depress EPSCs in the rat rostral nucleus accumbens in vitro.

Authors:  Samuel B Kombian; Kethireddy V V Ananthalakshmi; Subramanian S Parvathy; Wandikayi C Matowe
Journal:  J Physiol       Date:  2003-12-12       Impact factor: 5.182

7.  Reversal of CRF- and dopamine-induced stimulation of colonic motility by CCK and igmesine (JO 1784) in the rat.

Authors:  M Gué; C Gleïzes-Escala; C Del Rio-Lacheze; J L Junien; L Buéno
Journal:  Br J Pharmacol       Date:  1994-03       Impact factor: 8.739

8.  Opposite effects mediated by CCKA and CCKB receptors in behavioural and hormonal studies in rats.

Authors:  P T Männistö; A Lang; J Harro; E Peuranen; J Bradwejn; E Vasar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-05       Impact factor: 3.000

Review 9.  Cholecystokinin receptor subtypes: role in the modulation of anxiety-related and reward-related behaviours in animal models.

Authors:  Susan Rotzinger; Franco J Vaccarino
Journal:  J Psychiatry Neurosci       Date:  2003-05       Impact factor: 6.186

10.  Regulation by the neuropeptide cholecystokinin (CCK-8S) of protein phosphorylation in the neostriatum.

Authors:  G L Snyder; G Fisone; P Morino; V Gundersen; O P Ottersen; T Hökfelt; P Greengard
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.